Key result
Maternal and infant RSV immunization shows feasibility in LMICs when integrated into existing health programs.
Why the study?
Are maternal and infant RSV immunization options feasible and acceptable in low- and middle-income countries?
Are maternal and infant RSV immunization options feasible and acceptable in low- and middle-income countries?
Maternal and infant RSV immunization options are considered acceptable and feasible in LMICs if integrated into existing public health programs.
Both maternal and infant RSV immunization options were viewed as acceptable and feasible if integrated into existing public health programs. Introduction decisions will require additional country-specific considerations, including community acceptability of option(s), health system/workforce capacity, availability of relevant epidemiology data, and product affordability. These findings can guide policymakers as they prepare for potential RSV prevention product introduction and scale-up.
No takes yet. Share an insight, caveat, or question.
Quintanar-Solares et al. (2026) studied this question. Maternal and infant RSV immunization options are considered acceptable and feasible in low- and middle-income countries if integrated into existing public health programs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: